Global Europe Influenza Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

The Europe Influenza market is growing at a significant CAGR due to increase in geriatric population. Increase in vaccination awareness, rising investment by companies in research and development activities, and increasing number of immunization programs organized by the government are the major factors fuelling the growth of Europe influenza market over the forecast period. The major market players have great pipeline products, Initiatives by government bodies such as WHO to ECDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of Europe influenza market over the forecast period. However, lack of required funding, limited opportunities for the production of vaccines, and stringent regulatory policies for new product approvals might hamper the growth of Europe Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increasing prices of Influenza diagnostic kits, and difficulties in the storage of inventory also hinder the Europe influenza market.

A sample of this report is available upon request :
https://www.precisionbusinessinsights.com/market-reports/global-europe-influenza-market/#ulp-4H8Z4LpNMLEuOnnx

The Europe influenza market is segmented on the basis of product type, distribution channel, and end user

Based on drug class, Europe influenza market is segmented into the following:
Anti-viral drugs
Zanamivir
Oseltamivir
Amantadine
Rimantadine
Others
Interferons
Vaccines
Trivalent
Quadrivalent

Based on route of administration, Europe influenza market is segmented into the following:
Oral
Parenteral
Others

Based on end-user, Europe influenza market is segmented into the following:
Hospital pharmacies
Retail pharmacies
Others

To view TOC of this report is available upon request :
https://www.precisionbusinessinsights.com/market-reports/global-europe-influenza-market/#ulp-c654SbFYO64MsOhu

Several international players in Europe are actively involved in the development of vaccines and drugs for influenza treatment to increase its market share. Vaccines are majorly preferred for the influenza treatment which is key revenue contributor for the growth of Europe Influenza market share. Launching of new products, technological innovations, and approvals from European Medical Agency for various drugs might fuel the growth of Europe Influenza market. For instance, in July 2016, Sanofi Pasteur MSD announced the approval of the latest addition to its family of influenza vaccines in the UK. Similarly, during 2009, three vaccines Celvapan, Pandemrix, and Focetria were authorized as the mock-up vaccines and converted into the pandemic-influenza vaccines after the identification of A/H1N11 flu strain. Similarly, two vaccines Humenza and Arepanrix were authorized using the emergency procedure and contributed renewed interest in the Europe influenza market.

Need more information about this report :
https://www.precisionbusinessinsights.com/market-reports/global-europe-influenza-market/#ulp-14mlyhjMGhVjZqa3

Europe holds a dominant share in the global influenza market. The largest share is attributed to rising awareness regarding the influenza virus and disease, raising investment by companies in research and development, and increasing number of immunization programs organized by the government are some of the factors driving the Europe Influenza Market. The increase in the prevalence of influenza in the European region is a major driving factor for the growth of European Influenza market. According to EMEA, approximately 15,000 people die of the severe consequence of influenza. Similarly, change in lifestyle, food habituations, and climatic conditions in European countries such as Austria, Germany, U.K., Spain, and Switzerland, among others also increase the growth of Europe Influenza market.

Get access to full summary:
https://www.precisionbusinessinsights.com/market-reports/global-europe-influenza-market/

Some of the players in Europe influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline Plc. (U.K.), Novartis AG (Switzerland), Sanofi (France), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals.Inc. (U.S.), and Abbott Laboratories Inc. (U.S.) to name a few.

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553

This release was published on openPR.